$16.75
1.64% day before yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$16.75
-4.51 21.21% 1M
-11.15 39.96% 6M
-9.90 37.15% YTD
-7.47 30.84% 1Y
-2.73 14.01% 3Y
-18.90 53.02% 5Y
-4.65 21.73% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.27 1.64%
ISIN
US14843C1053
Symbol
CSTL
Sector

Key metrics

Market capitalization $483.61m
Enterprise Value $234.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.84
EV/Sales (TTM) EV/Sales 0.68
P/S ratio (TTM) P/S ratio 1.39
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth 38.43%
Revenue (TTM) Revenue $347.08m
EBIT (operating result TTM) EBIT $-13.79m
Free Cash Flow (TTM) Free Cash Flow $48.44m
Cash position $275.15m
EPS (TTM) EPS $-0.20
P/E forward negative
P/S forward 1.65
EV/Sales forward 0.80
Short interest 6.00%
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

Buy
100%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
347 347
38% 38%
100%
- Direct Costs 102 102
72% 72%
29%
245 245
28% 28%
71%
- Selling and Administrative Expenses 166 166
1% 1%
48%
- Research and Development Expense 50 50
4% 4%
15%
29 29
198% 198%
8%
- Depreciation and Amortization 42 42
232% 232%
12%
EBIT (Operating Income) EBIT -14 -14
67% 67%
-4%
Net Profit -5.07 -5.07
84% 84%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
GlobeNewsWire
9 days ago
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uv...
Neutral
GlobeNewsWire
11 days ago
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month
Neutral
Seeking Alpha
12 days ago
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Matthew Goldberg - Senior Vice President, Medical Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiaban...
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 761
Founded 2007
Website www.castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today